On September 1, 2020 Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that management will participate in four investor conferences in September (Press release, Eiger Biopharmaceuticals, SEP 1, 2020, View Source [SID1234564259]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Citi’s 15th Annual BioPharma Conference. Eiger will participate in two panels:
"COVID-19 Therapeutics" on Wednesday, September 9, 9:50-10:20 AM ET
"Challenges and Opportunities in Rare Disease Drug Development" on Wednesday, September 9, 4:15-4:45 PM ET
Baird Global Healthcare Conference 2020. Eiger will present a corporate update on Wednesday, September 9, 12:50-1:20 PM ET.
H.C. Wainwright 22nd Annual Global Investment Conference from September 14- September 16.
Cantor Global Virtual Healthcare Conference 2020. Eiger will present a corporate update on Thursday, September 17, 2:00-2:30 PM ET.
Eiger will host one-on-one meetings at all conferences. Live webcasts of the Citi panels and Baird and Cantor presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.